Consistently low MIC values – a potent addition to the treatment options for cSSTI1,2,*
Header | ||
---|---|---|
Header | Header | Header |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Adapted from Garrison MW, et al. 2012.
*Potency has been demonstrated in clinical studies of cSSTI against pathogens that were susceptible to antibiotics in vitro. In vitro activity does not always correlate with clinical efficacy.
CAP, community-acquired pneumonia; CA-MRSA, community-acquired methicillin-resistant Staphylococcus aureus; cSSTI, complicated skin and soft tissue infection; h-VISA, heterogeneous vancomycin-intermediate Staphylococcus aureus; MIC, minimum inhibitory concentration; VISA, vancomycin-intermediate Staphylococcus aureus; VRSA, vancomycin-resistant Staphylococcus aureus.
References:
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.